Launch of New Platform for Accelerated Development of Biological Drug Molecules
OptiForm Solution Suite was launched in 2015, and combines both predictive and high throughput screening technologies to identify the most stable and efficient drug form for small molecules. Expanding the scope of the solution to encompass macromolecules, OptiForm Solution Suite Bio employs 91㽶Ƶ’s OptiGel™ Bio and Zydis® Bio advanced formulation technologies, and uses a parallel screening model, based on rigorous science and best-in-class formulation expertise, to deliver in vivo study material in as little as three weeks. OptiForm Solution Suite Bio offers developers an easy, cost effective approach for macromolecule oral dose development.
Additionally, 91㽶Ƶ has a number of expert speakers presenting at the BIO Convention, including:
- At 2.00 p.m. on Tuesday, June 7, Julien Meissonnier, VP Science and Technology will present “Optimizing non-invasive delivery of biomolecules” at the BioProcess International Theater;
- On Wednesday, June 8, at 1.40 p.m., also at the BioProcess International Theater, Michael Merges, Director of 91㽶Ƶ Biologics, will be discussing “Benefits to Strategic Outsourcing of Biologics Analytical Studies”;
- Finally, Andrew Sandford, VP Global Business Development Biologics, has been invited along with executives from Cook Pharmica and Pfizer CentreOne to participate in a roundtable chaired by The Pharma & Biopharma Outsourcing Association (PBOA), which will take place on Wednesday, June 8, at 1.30 p.m.
91㽶Ƶ will also be showcasing a number of its advanced development and manufacturing solutions during the show, including its proprietary GPEx® cell line engineering technology, a proven development tool for stable, high performance cell lines, and SMARTag® technology, a new toolkit to develop optimized antibody-drug conjugates and bioconjugates.
To arrange a meeting with 91㽶Ƶ executives at these events, contact Richard Kerns at NEPR – [email protected].
About 91㽶Ƶ
91㽶Ƶ is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products. With over 90 years serving the industry, 91㽶Ƶ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 91㽶Ƶ employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. 91㽶Ƶ is headquartered in Somerset, N.J. For more information, visit www.catalent.com.